Uveal Effusion Syndrome (UES)

Uveal Effusion Syndrome (UES) is a rare eye condition where fluid collects in the potential space around the uveal tissues—the choroid, the ciliary body, and sometimes under the retina—without a tear in the retina. This fluid build-up leads to serous (exudative) detachments of the choroid and the retina. In simple words, fluid seeps and gets trapped behind the retina and in the wall of the eye, causing the retina to lift up in places and blur the vision. In many patients the eye wall (sclera) is abnormally thick or stiff, which blocks normal outward movement of proteins and fluid through the sclera and can also squeeze the vortex veins (the main drainage veins of the choroid). Both problems—poor fluid escape and venous congestion—encourage fluid to pool and create the effusions and detachments seen in UES. EyeWiki

Uveal Effusion Syndrome is a rare, non-tear-related swelling and fluid build-up inside the eye wall, where thick or abnormal sclera prevents normal fluid escape and sometimes compresses large draining veins. The trapped fluid lifts the choroid and can lift the retina, causing painless blurry or distorted vision. It can affect one or both eyes, may be mistaken for inflammation or tumors, and often needs special imaging and, in many cases, a surgical “pressure-release” procedure on the sclera called scleral windows to let fluid out and allow the retina to settle back. EyeWikiRetina Today

Uveal Effusion Syndrome (UES) is a rare eye disorder where fluid collects inside the wall of the eye, in the layer called the uvea (which includes the iris, ciliary body, and choroid). This trapped fluid makes the choroid swell (a choroidal effusion) and can also lift the retina off the back of the eye without a tear (a serous retinal detachment). In simple terms, the eye wall becomes “water-logged,” and that swelling pushes the retina and other inner layers away from where they should sit, which can blur or distort vision. UES is not due to an obvious tear or hole; the problem is fluid build-up and poor fluid outflow through a thick or abnormal sclera (the white outer coat of the eye). EyeWikiRetina Today

Why does UES happen?

Two related ideas explain most cases:

1. Impaired drainage through the sclera: If the sclera is thick or structurally abnormal, fluid that normally seeps out through microscopic channels cannot escape. It accumulates in the suprachoroidal space, causing the choroid to bulge. EyeWikiScienceDirect

2. Compression of vortex veins: Thick sclera can also squeeze the large veins (vortex veins) that drain blood from the choroid, backing up fluid and raising hydrostatic pressure so fluid leaks into tissue spaces. Retina Today

These mechanisms often occur in nanophthalmos (a very small, hyperopic eye with a thick, inelastic sclera) but can also occur in normal-sized eyes with scleral changes. EyeWiki

Researchers have shown that in many cases of UES, especially those linked with nanophthalmos (unusually small eyes), the sclera is thicker and contains disorganized collagen and excess proteoglycans. This abnormal sclera reduces scleral permeability, traps albumin in the suprachoroidal space, and creates an osmotic gradient that draws in more fluid—further feeding the effusion. The same thick sclera can compress vortex veins, slowing venous outflow and congesting the choroid. These two forces—blocked protein/ fluid diffusion and venous congestion—together explain the typical fluid build-up in UES. EyeWikiWebEyePMC

Although many detachments from fluid around or under the retina have obvious external causes (such as inflammation, tumor, surgery, or very low eye pressure), UES is diagnosed when these other causes are ruled out and the clinical picture fits the syndrome. It is uncommon, often misdiagnosed at first, and can be vision-threatening if not recognized. Retina Today

---

Types

Doctors often sort UES into three groups based on eye size and scleral findings (commonly called the Uyama types):

1. Type 1 (Nanophthalmic UES). The eye is small (short axial length, often ~16 mm) and highly farsighted. The sclera is typically abnormally thick. This group commonly shows the classic scleral problem that blocks fluid/protein movement and may compress vortex veins. EyeWikiScienceDirect

2. Type 2 (Non-nanophthalmic with abnormal sclera). The eye is normal in size, but the sclera still looks and behaves abnormal (thick/rigid on imaging or histology). The fluid problem arises from the same physical barriers in the sclera and possible venous compression. EyeWiki

3. Type 3 (Non-nanophthalmic with normal sclera). The eye is normal in size and the sclera appears normal by usual tests. Despite that, the clinical picture fits UES. This rare form often needs multimodal imaging (like ICGA, UBM, OCT) to make the diagnosis and to exclude look-alike diseases. PMC

These types are clinically useful. They remind us that UES is not a single look—it ranges from very small thick-walled eyes (type 1) to normal-sized eyes with either measurable scleral disease (type 2) or seemingly normal sclera (type 3). PMC

---

Causes

“Causes” here are best understood as root mechanisms or associated conditions that either produce the UES picture or must be ruled out before calling a case “idiopathic UES.” UES itself is often idiopathic and sclera-driven, but choroidal/uveal effusions also happen in many other settings that can mimic or overlap with UES. Clinicians work through this list to avoid missing a treatable underlying problem.

1. Abnormally thick or rigid sclera – slows protein and fluid diffusion out through the sclera, raising osmotic pull that traps fluid. EyeWiki

2. Vortex vein compression – thick sclera can pinch venous outflow, congesting the choroid and encouraging leakage. EyeWikiScienceDirect

3. Nanophthalmos – a small eye with thick sclera and narrow angles, strongly linked with UES pathophysiology. EyeWiki

4. Abnormal scleral collagen/proteoglycans – histology shows disorganized collagen and proteoglycan deposition, supporting a structural barrier to outward fluid flow. EyeWiki

5. Reduced scleral permeability to albumin – albumin gets trapped in the suprachoroidal space, pulling more fluid in. EyeWiki

6. Increased choroidal thickness / congestion – especially visible on ICGA and enhanced-depth OCT; reflects venous stasis. PMC

7. Post-operative hypotony (very low eye pressure), especially after glaucoma filtration surgery – can cause choroidal effusions that mimic UES; must be excluded. EyeWiki

8. Posterior scleritis – an inflammatory disease of the sclera that can produce exudative detachments resembling UES. EyeWiki

9. Pars planitis or uveitis – inflammatory conditions can lead to exudative retinal detachment; this is a key differential. ScienceDirect

10. Vogt-Koyanagi-Harada (VKH) disease – autoimmune inflammation of the uvea that causes serous detachments; an important mimicker. WebEyeTaylor & Francis Online

11. Intraocular tumors (e.g., choroidal melanoma, metastasis) – can cause exudative detachments; UES should not be diagnosed until tumors are ruled out. EyeWiki

12. Medication-related choroidal effusions (e.g., certain sulfa-related drugs like topiramate have been reported to cause effusions/angle closure) – secondary effusions should be excluded before labeling UES. EyeWiki

13. Trauma – blunt injury may lead to uveal/choroidal effusion; again, this makes the case secondary rather than idiopathic UES. ScienceDirect

14. Severe systemic hypertension – can accompany or worsen exudative detachments; must be evaluated. EyeWiki

15. Inflammatory masquerade (intraocular lymphoma) – lymphoma can mimic uveitis/UES and produce subretinal fluid; must be ruled out. Retina TodayScienceDirect

16. Elevated episcleral venous pressure / venous outflow problems – can contribute to choroidal congestion and effusion-like changes. (Mechanistic inference aligned with venous congestion concept.) ScienceDirect

17. Surgical scleral buckle or orbital surgery effects – can alter choroidal hemodynamics and lead to effusions in some contexts; part of the broader differential. (General inference consistent with exudative mechanisms.) ScienceDirect

18. Idiopathic pachychoroid physiology – a thick choroid with venous dilation may overlap with UES-like congestion in select cases; needs careful imaging to separate from central serous chorioretinopathy. PMC

19. Systemic inflammatory disease (e.g., sarcoidosis, lupus) – can cause posterior segment inflammation with exudation; UES requires excluding these. WebEye

20. Primary idiopathic cases with normal sclera (Type 3) – after all secondary causes above are excluded, some patients still meet the UES picture with normal sclera on tests. PMC

Symptoms

1. Blurred vision – the commonest complaint; fluid under/around the retina distorts the light signal. EyeWiki

2. Sudden or subacute drop in vision – if a larger area of retina detaches or the macula is involved, vision can fall noticeably. Retina Today

3. Metamorphopsia – straight lines look wavy because the detached retina is uneven. (Mechanism consistent with exudative maculopathy.)

4. Scotomas – dark or missing patches in the visual field when detachment crosses photoreceptor pathways.

5. Micropsia – objects appear smaller if the macula is lifted even slightly.

6. Photopsia (flashes) – mechanical stimulation of the retina by shifting fluid can cause light flashes in some patients.

7. Floaters – small, drifting spots; may accompany effusions, though not specific.

8. Color desaturation – colors can look washed-out when the macula is affected.

9. Nyctalopia (poor night vision) – retinal dysfunction from subretinal fluid can reduce low-light performance.

10. Visual field constriction – peripheral detachments cause edge-field loss or shadows.

11. Shifting vision – symptoms may change with posture if subretinal fluid redistributes (“shifting fluid”). EyeWiki

12. Headache or eye pressure sensation – some report a heavy feeling, particularly if IOP is normal-to-high. EyeWiki

13. No significant pain – important clue: pain is typically absent, helping distinguish UES from posterior scleritis, which is often painful. EyeWiki

14. Hyperopic shift – in nanophthalmos, the short eye length is linked with farsightedness; symptoms of reading blur are common. EyeWiki

15. Bilateral involvement over time – though sometimes one eye is worse, monitoring the fellow eye is important due to risk of bilateral disease. (Supported by series on UES behavior.) Retina Today

---

Diagnostic Tests

Below are 20 tests, grouped by how a clinician uses them. The goal is to confirm UES, map fluid and tissue changes, and exclude other diseases (like tumor, VKH, posterior scleritis, inflammatory or malignant masquerades). Citations are included where the test’s role is especially emphasized in the literature.

A) Physical Exam

1. Best-corrected visual acuity (BCVA). Measures how clearly you see with your best glasses. A drop in BCVA signals macular involvement or widespread detachment. (Foundation test across UES series.) Lippincott Journals

2. Pupil exam (RAPD check). Looks for relative afferent pupillary defect; most UES patients do not have a strong RAPD unless there is extensive retinal dysfunction, aiding differentiation from optic nerve problems.

3. Intraocular pressure (IOP) assessment. In UES, IOP is classically normal or even elevated, which helps separate it from hypotony-related effusions unless postoperative causes are present. EyeWiki

4. Slit-lamp anterior segment exam. Checks for inflammation signs (cells, flare), narrow angles (common in nanophthalmos), or clues pointing to other conditions (e.g., scleritis). EyeWiki

B) Manual Tests (at the chair)

5. Indirect ophthalmoscopy with scleral depression. A hands-on retinal exam that maps peripheral choroidal/retinal detachments and looks for retinal tears (absent in UES). (Core clinical step across reports.) EyeWiki

6. Gonioscopy. A mirrored lens is used to directly view the drainage angle; helps identify crowded/narrow angles in nanophthalmos and excludes angle-related secondary issues. EyeWiki

7. Confrontation visual fields. A quick bedside check for field defects from peripheral detachments; formal perimetry may follow.

8. Amsler grid / near grid testing. Detects metamorphopsia and subtle macular distortion due to subretinal fluid.

C) Lab and Pathology

9. Inflammatory markers (ESR, CRP). Help screen for active systemic inflammation when uveitis or scleritis is suspected in the differential. WebEye

10. Autoimmune panel (ANA and related tests). Looks for autoimmune diseases that can mimic or cause exudative detachments, such as VKH-like syndromes or connective tissue disease. WebEye

11. Infectious workup (syphilis serology, TB-IGRA). Syphilis and tuberculosis can mimic posterior uveitis with exudation; excluding them is standard when the picture is unclear. WebEye

12. Serum ACE/lysozyme (sarcoidosis screen). Sarcoidosis is another posterior uveitis mimicker; positive tests push evaluation away from idiopathic UES. WebEye

13. Cytology/biopsy when lymphoma is suspected. If findings suggest a masquerade syndrome (e.g., vitreous cells that do not behave like inflammation), directed tissue studies help exclude intraocular lymphoma. ScienceDirect

D) Electrodiagnostic

14. Full-field electroretinography (ERG). Measures global retinal function. In pure UES, ERG is often near-normal or only mildly affected; a markedly abnormal ERG suggests another retinal disease. (Used selectively to sort out mimics.)

15. Visual evoked potentials (VEP). Assesses the optic pathway. A normal VEP with visual loss pushes toward retinal (not optic nerve) causes, fitting an exudative detachment pattern.

E) Imaging Tests

16. B-scan ultrasonography. An ultrasound probe images the back of the eye, showing choroidal detachments, thick choroid, and even suprachoroidal fluid when the view is cloudy. It is a workhorse test in UES. PMC

17. Ultrasound biomicroscopy (UBM). High-frequency ultrasound aimed at the anterior sclera can measure scleral thickness and visualize ciliary body detachment. It is especially helpful in nanophthalmos and in type 2 UES. EyeWiki

18. Optical coherence tomography (OCT). Cross-sectional “microscope” of the retina showing subretinal fluid, retinal thickening, and on enhanced-depth modes, choroidal thickening. OCT documents macular involvement and progress over time. Lippincott Journals

19. Fluorescein angiography (FA). Dye study that helps rule out other causes of exudative detachment (like central serous chorioretinopathy patterns) and can show late pooling. In chronic UES, leopard-spot RPE changes may be seen clinically. EyeWiki

20. Indocyanine green angiography (ICGA). Highlights the choroidal vasculature; in UES, late ICGA hyperfluorescence suggests choroidal congestion, useful in type 3 where sclera looks normal and diagnosis is tricky. PMC

Non-Pharmacological Treatments (therapies and others)

Below, each item includes Description, Purpose, and Mechanism in simple language. These measures complement medical and surgical care; several are supportive while definitive treatment often requires surgery in Types 1–2.

1. Careful Observation (watchful waiting)
   Description: Regular follow-ups with vision checks and imaging if symptoms are mild.
   Purpose: Avoid unnecessary drugs or surgery when the detachment is small or stable.
   Mechanism: Some limited effusions can settle as transient fluid shifts normalize; monitoring catches any worsening early.

2. Head Elevation During Rest
   Description: Sleep with the head raised 20–30 degrees.
   Purpose: Reduce fluid pooling at the back of the eye.
   Mechanism: Gravity helps shift fluid away from the macula, which may lower retinal swelling.

3. Avoid Valsalva-Type Strain
   Description: Reduce heavy lifting, hard coughing when possible, or straining with constipation.
   Purpose: Prevent sudden spikes in venous pressure.
   Mechanism: Lower venous pressure reduces choroidal congestion.

4. Medication Review and Withdrawal of Offending Drugs
   Description: Work with your doctor to stop or switch medicines known to cause choroidal effusions (for example, topiramate or rapid shifts in certain glaucoma drops) if relevant.
   Purpose: Remove triggers that can mimic or worsen UES-like effusions.
   Mechanism: Prevents drug-induced ciliary body swelling and suprachoroidal fluid. (UES remains distinct, but this avoids confounders.) EyeWiki

5. Protective Timing of Cataract or Other Intraocular Surgery
   Description: If you need eye surgery and have nanophthalmos/UES, your surgeon may stage procedures or create scleral windows first.
   Purpose: Reduce the risk of postoperative effusions.
   Mechanism: Pre-emptive scleral windows relieve outflow resistance before intraocular manipulation. Review of Ophthalmology

6. Careful Control of Systemic Fluid Balance
   Description: Manage hypertension, sleep apnea, and salt intake with your physician.
   Purpose: Reduce venous congestion that can worsen choroidal swelling.
   Mechanism: Lower venous pressure and edema can reduce fluid seepage into the choroid.

7. Nutritional Anti-Inflammatory Pattern (see diet section)
   Description: Emphasize whole, unprocessed foods with adequate hydration.
   Purpose: Support vascular health and tissue healing.
   Mechanism: Low-salt, antioxidant-rich diets can limit fluid retention and oxidative stress (supportive, not curative).

8. Treat Co-existing Ocular Surface Inflammation
   Description: Manage blepharitis/allergy that can complicate exam and treatment.
   Purpose: Improve comfort and allow accurate imaging.
   Mechanism: Reduced surface inflammation improves measurement quality and compliance.

9. Blue-light and Glare Management
   Description: Use appropriate tints or filters if vision is hazy.
   Purpose: Reduce visual discomfort and photophobia.
   Mechanism: Filters limit scatter on a swollen retina.

10. Protective Eyewear and Safe Activity
    Description: Prevent eye trauma.
    Purpose: Avoid secondary problems like hemorrhage or retinal tears.
    Mechanism: Mechanical protection lowers risk of added pathology in a compromised eye.

11. Smoking Cessation
    Description: Quit smoking with supportive programs.
    Purpose: Improve microvascular health.
    Mechanism: Better choroidal circulation may reduce congestion.

12. Weight Management and Exercise (as cleared by your doctor)
    Description: Moderate aerobic activity and weight control.
    Purpose: Improve cardiovascular status and venous return.
    Mechanism: Better venous tone may reduce choroidal stasis.

13. Sleep Hygiene
    Description: Regular sleep schedule and treating apnea.
    Purpose: Stabilize systemic BP and venous pressures overnight.
    Mechanism: Fewer pressure spikes limit fluid shifts.

14. Avoid Dehydration and Extreme Fluid Loading
    Description: Aim for steady, adequate hydration.
    Purpose: Prevent vascular instability.
    Mechanism: Stable osmotic conditions reduce fluid seepage.

15. Monitor Intraocular Pressure (IOP) Closely
    Description: Scheduled pressure checks.
    Purpose: Catch hypotony or spikes that may change choroidal fluid dynamics.
    Mechanism: Pressure extremes can drive fluid into or out of the suprachoroidal space.

16. Patient Education and Symptom Diary
    Description: Track vision, distortion, and scotomas.
    Purpose: Recognize early macular involvement.
    Mechanism: Timely reporting prompts imaging and intervention.

17. Prudent Caffeine and Alcohol Use
    Description: Avoid large swings.
    Purpose: Reduce BP/vascular variability.
    Mechanism: Smoother hemodynamics may lessen congestion.

18. Manage Constipation
    Description: Fiber, fluids, and gentle stool softeners if needed.
    Purpose: Reduce straining.
    Mechanism: Less Valsalva means lower choroidal venous pressure.

19. Sun and Heat Moderation
    Description: Avoid prolonged heat exposure that dilates vessels.
    Purpose: Limit vasodilation-related congestion.
    Mechanism: Cooler environments reduce venous pooling.

20. Prompt Evaluation of Any New Visual Symptoms
    Description: Do not wait if metamorphopsia, a curtain, or central blur appears.
    Purpose: Protect the macula.
    Mechanism: Early action shortens the time the retina stays lifted.

---

Drug Treatments

Important: Medication choice depends on UES type and the treating specialist’s judgment. Types 1–2 (abnormal sclera) often do not respond well to medicines alone and usually need scleral windows. Type 3 (no scleral abnormality) may respond to medical therapy. Doses are common ranges; your doctor will individualize them. EyeWikiSpringerLink

1. Prednisone (systemic corticosteroid)
   Class: Corticosteroid (anti-inflammatory).
   Typical Dosage/Time: 0.5–1 mg/kg/day orally, then tapered over weeks if responsive.
   Purpose: Reduce choroidal inflammation and vascular leakage.
   Mechanism: Stabilizes endothelial barriers and lowers inflammatory mediators.
   Side effects: Elevated glucose, mood change, infection risk, hypertension, gastric irritation.

2. Acetazolamide (systemic carbonic anhydrase inhibitor)
   Class: Carbonic anhydrase inhibitor.
   Typical Dosage/Time: 250 mg orally 2–4×/day or as sustained-release, short course to longer if effective.
   Purpose: Reduce fluid production and aid retinal reattachment in select cases.
   Mechanism: Lowers aqueous production; may alter choroidal fluid dynamics.
   Side effects: Paresthesias, fatigue, kidney stones, metabolic acidosis, sulfa allergy issues.

3. Topical Beta-Blockers (e.g., Timolol)
   Class: Glaucoma drop (aqueous suppressant).
   Typical Dosage/Time: 1 drop once or twice daily.
   Purpose: Modestly lower IOP if elevated.
   Mechanism: Reduced aqueous humor production may lessen uveal congestion.
   Side effects: Bradycardia, bronchospasm (systemic absorption), dry eye.

4. Topical Carbonic Anhydrase Inhibitors (e.g., Dorzolamide)
   Class: Aqueous suppressant.
   Typical Dosage/Time: 1 drop 2–3×/day.
   Purpose: Adjunct IOP control.
   Mechanism: As above, but topical.
   Side effects: Stinging, bitter taste, rare allergy.

5. Cycloplegics (e.g., Atropine 1% or Cyclopentolate)
   Class: Antimuscarinic.
   Typical Dosage/Time: 1–2×/day short course.
   Purpose: Relax ciliary spasm and deepen the anterior chamber in effusion-related shallowing.
   Mechanism: Paralysis of ciliary body reduces forward rotation and discomfort.
   Side effects: Light sensitivity, near blur, systemic anticholinergic effects.

6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs; e.g., Indomethacin)
   Class: NSAID.
   Typical Dosage/Time: Indomethacin 25–50 mg orally 2–3×/day (GI protection as needed).
   Purpose: Anti-inflammatory adjunct in steroid-responsive Type 3 UES.
   Mechanism: COX inhibition reduces prostaglandin-mediated leakage.
   Side effects: Gastritis, ulcers, kidney effects; avoid in sensitive patients.

7. Intravitreal Steroid (e.g., Triamcinolone) – selective use
   Class: Local corticosteroid.
   Typical Dosage/Time: Single injection (dose per formulation), sometimes repeated.
   Purpose: Targeted reduction of macular fluid when systemic therapy is unsuitable.
   Mechanism: Local anti-inflammatory barrier stabilization.
   Side effects: IOP rise, cataract progression, infection risk (rare).

8. Systemic Immunomodulators (rare; case-by-case)
   Class: Steroid-sparing agents (e.g., methotrexate, mycophenolate) when inflammation is suspected and UES overlaps with uveitis features.
   Dosage/Time: Specialist-directed.
   Purpose: Reduce steroid exposure where inflammatory drivers are significant (more typical for uveitis than classic UES).
   Mechanism: Dampen immune activation.
   Side effects: Bone marrow suppression, liver effects; close monitoring required.

9. Hyperosmotic Agents (e.g., Oral Glycerol or IV Mannitol) – short-term
   Class: Osmotic diuretic.
   Dosage/Time: Acute use during severe pressure spikes.
   Purpose: Temporary IOP reduction to improve comfort/visibility before surgery.
   Mechanism: Draws fluid out from ocular tissues.
   Side effects: Nausea, electrolyte shifts; hospital setting for IV.

10. Avoid/Use Caution: Prostaglandin Analogs
    Comment: Some prostaglandin drops have been associated with choroidal effusions in special settings; they are not first-line in UES. Use only if a glaucoma specialist feels benefits outweigh risks. EyeWiki

Overall evidence note: In Types 1–2, medicines alone frequently fail; surgery (scleral windows) is usually needed. Type 3 is more likely to improve with medical therapy. SpringerLink

---

Dietary “Molecular” Supplements

There are no supplements proven to cure UES. The following are general eye-health or anti-inflammatory supports sometimes used in retinal care. Always discuss with your doctor, especially if surgery is planned or if you take blood thinners.

1. Omega-3 (EPA+DHA) — 1000–2000 mg/day combined.
   Function: Anti-inflammatory; supports vascular health.
   Mechanism: Resolvin/Protectin pathways reduce cytokine-mediated permeability.

2. Lutein (10 mg/day) + Zeaxanthin (2 mg/day)
   Function: Macular pigment support; antioxidant.
   Mechanism: Filters blue light; quenches reactive oxygen species.

3. Vitamin C (≈500 mg/day)
   Function: Antioxidant; collagen support.
   Mechanism: Reduces oxidative stress in vascular tissue.

4. Vitamin E (up to 400 IU/day)
   Function: Lipid-phase antioxidant.
   Mechanism: Protects membranes from peroxidation.

5. Zinc (10–25 mg/day elemental; avoid high chronic dosing without doctor guidance)
   Function: Enzyme cofactor; retinal support.
   Mechanism: Stabilizes antioxidant enzymes.

6. Curcumin (500–1000 mg/day with piperine unless contraindicated)
   Function: Anti-inflammatory.
   Mechanism: NF-κB pathway modulation.

7. Quercetin (500 mg/day)
   Function: Flavonoid antioxidant.
   Mechanism: Reduces oxidative signaling.

8. Pycnogenol or Grape-seed Extract (per label)
   Function: Microvascular support.
   Mechanism: Improves endothelial function and capillary integrity.

9. Magnesium (200–400 mg/day unless restricted)
   Function: Vascular tone and neuromuscular support.
   Mechanism: Smooth muscle relaxation; may steady BP variability.

10. Coenzyme Q10 (100–200 mg/day)
    Function: Mitochondrial support.
    Mechanism: Improves cellular energy and limits oxidative injury.

Reminder: These are adjuncts, not treatments for scleral outflow problems central to UES.

---

Regenerative / Stem Cell” Drugs

For UES, there are no approved “immunity booster,” regenerative, or stem-cell drugs with proven benefit. Using powerful immunotherapies without a specific inflammatory diagnosis can be harmful. Where inflammation is present (misdiagnosed uveitis, for example), specialists may use standard immunomodulators (e.g., methotrexate or mycophenolate) to control inflammation—not to “boost” immunity, but to modulate it. For true UES Types 1–2, the core problem is scleral outflow resistance, not an immune deficiency. The most effective intervention is surgical scleral windows in appropriate candidates. EyeWikiSpringerLink

To honor your requested section count, here are six entries explaining why such drugs are not appropriate for classic UES:

1. Stem-cell infusions: Not indicated; no evidence of benefit in UES; risks include immune reactions and ectopic tissue growth.

2. Growth-factor injections: Not indicated; may worsen leakage by increasing vascular permeability.

3. Systemic biologics (TNF-α/IL inhibitors) without inflammation diagnosis: Not indicated; immunosuppression risks outweigh unproven benefit.

4. High-dose IVIG: Not indicated; no mechanism to fix scleral outflow.

5. “Immune boosters” (over-the-counter blends): Marketing term with no proven effect on UES; may interact with medications.

6. Experimental cell-based eye injections: Not ethical/approved for UES; risk of severe complications.

---

Surgeries

1. Partial-Thickness Sclerectomies (“Scleral Windows”)
   Procedure: The surgeon thins the outer sclera in two to four quadrants (often with small sclerostomies, tiny full-thickness openings), creating “windows” for fluid to exit.
   Why: This is the standard, proven surgery for Types 1–2 UES with thick sclera; it reduces resistance and decompresses the choroid so the retina can settle. High success rates are reported, sometimes after one or two procedures. AAO JournalPubMedFrontiersPMC

2. Vortex Vein Decompression (historical/selected cases)
   Procedure: Surgical exposure and decompression of vortex veins.
   Why: To relieve venous outflow obstruction when thought to be a major contributor. Used less commonly today compared with scleral windows. PubMed

3. Suprachoroidal Fluid Drainage
   Procedure: Controlled drainage of fluid from the suprachoroidal space via sclerotomy, sometimes combined with scleral windows.
   Why: Rapidly reduces choroidal elevation and allows retinal reattachment in severe cases or to facilitate visualization during surgery. Retina Today

4. Quadrantic Lamellar Sclerectomy with Sclerostomy (modern refinement)
   Procedure: Planned four-quadrant lamellar thinning plus one or more sclerostomies.
   Why: Widely used contemporary approach with good anatomical outcomes in case series. Frontiers

5. Prophylactic Scleral Windows Before Intraocular Surgery in Nanophthalmos
   Procedure: Creating windows before cataract or other intraocular surgery in high-risk small eyes.
   Why: Prevents postoperative uveal effusion by improving outflow in advance. Review of Ophthalmology

Outcomes note: Large reviews report high anatomical success with scleral window surgery and meaningful visual improvement in many eyes, though recurrences can occur and multiple windows may be needed. PubMed

---

Preventions

While you cannot fully “prevent” UES, you can lower risks of flare or confusion with look-alikes:

1. Pre-operative planning in nanophthalmos (consider prophylactic scleral windows). Review of Ophthalmology

2. Medication review before starting drugs known to induce effusions (e.g., topiramate). EyeWiki

3. Manage systemic BP and treat sleep apnea.

4. Avoid severe Valsalva/straining; treat constipation.

5. Moderate salt intake to reduce fluid retention.

6. Regular eye checks if you’re hyperopic or have a small eye.

7. Don’t skip follow-ups after eye surgery.

8. Quit smoking to improve microvascular health.

9. Healthy weight and activity for venous tone.

10. Promptly report new visual changes to your eye doctor.

---

When to See a Doctor (red flags)

• Immediately if you notice a new curtain/shadow, sudden distortion, or central blur, or if vision worsens quickly.

• Within 24–48 hours if you develop new photophobia, significant floaters, or if you have a small eye (nanophthalmos) with any new symptoms.

• Urgently if you are scheduled for intraocular surgery and have a known history of UES or nanophthalmos—pre-op planning can change the surgical approach.

---

What to Eat and What to Avoid

1. Eat: Leafy greens (spinach, kale) for lutein/zeaxanthin.

2. Eat: Oily fish (salmon, sardines) 2–3×/week for omega-3s.

3. Eat: Citrus and colorful fruits for vitamin C and antioxidants.

4. Eat: Nuts and seeds for vitamin E and minerals.

5. Eat: Whole grains and legumes for vascular health.

6. Avoid excess salt (helps limit fluid retention).

7. Avoid heavy alcohol (vascular swings).

8. Avoid megadose supplements without medical advice (possible interactions).

9. Limit ultra-processed foods that drive inflammation.

10. Steady hydration (neither dehydrated nor over-loaded).

---

Frequently Asked Questions

1) Is UES the same as a retinal tear?
No. UES causes serous retinal detachment from fluid under the retina without a tear. Tears are absent in classic UES. EyeWiki

2) Can UES happen in both eyes?
Yes. It can be bilateral, especially in small, thick-sclera eyes. EyeWiki

3) Will glasses fix the blur?
Usually not. The blur comes from the retina being lifted; once the retina reattaches, vision may improve.

4) Do eye drops cure UES?
Drops may help pressure or comfort, but in Types 1–2, surgery (scleral windows) is often needed for lasting anatomical success. PubMed

5) What is the success rate of surgery?
Case series show high anatomic success with scleral window surgery and good visual improvement in many eyes; some need more than one procedure. PubMed

6) Can UES come back after surgery?
Yes, recurrences can occur; additional windows may be required. PMC

7) How long does it take for vision to improve?
If the macula is involved, improvement may take weeks to months as the retina reattaches and recovers.

8) Is it painful?
UES is usually painless, though pressure sensations or headaches from strain can occur.

9) Can I travel by air?
Most patients can fly once the eye is stable; ask your surgeon if you recently had surgery or still have large effusions.

10) Are steroids always used?
They’re commonly tried, especially for Type 3, but they may not help Types 1–2 where scleral outflow is the main problem. SpringerLink

11) Could this be confused with other diseases?
Yes—posterior uveitis, intraocular lymphoma, and central serous chorioretinopathy can look similar; imaging and angiography help differentiate. Retina Today

12) Will I need both eyes operated?
Only if both eyes have clinically significant effusions that affect vision or surgery plans.

13) What are the main surgical risks?
Infection, bleeding, scarring, residual or recurrent effusion; your surgeon will outline specifics.

14) Do scleral windows change how my eye looks?
No visible change is expected; the work is on the outer white coat under the conjunctiva.

15) Is UES lifelong?
Many patients stabilize after appropriate treatment; long-term monitoring is wise because recurrences can happen.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 29, 2025.